ArticleInternational journal of general medicine2025
Levels of Sestrin-1 in Rheumatoid Arthritis Patients: Exploring the Association with Atherosclerosis.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reduced serum Sestrin-1 is associated with subclinical cardiovascular alterations in systemic lupus erythematosus: A controlled cross-sectional study.The Journal of international medical research · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is an autoimmune disease and affects various parts of the body, especially the joints, through inflammation. Sestrins are molecules that are known to have anti-inflammatory properties and have been shown to play a role in the stress response in the body. Methods: Our study is an observational study. Fifty-five RA patients followed in the Rheumatology outpatient clinic and 55 control groups with similar demographic characteristics to this patient group were included in the study. The disease activity scores, cardiac parameters and Sestrin-1 levels of the participants were measured and both groups were compared. Results: There were no differences observed between the two groups in demographic characteristics. Right Carotid intima media thickness (CIMT) levels were found to be significantly higher in RA patients (p = 0.036). Sestrin-1 levels were determined to be significantly lower in RA patients compared to the control group (p<0.001). According to multivariate analysis results, a 1 unit decrease in Sestrin-1 measurement reduces the risk of RA by 0.633 times (p = 0.031). Conclusion: Our study is the first to show that decreasing of Sestrin-1 may play a potential role of subclinical atherosclerosis in RA patients. However, the nature of this relationship and the potential role of Sestrin-1 in the treatment of RA still requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.